AcelRx , Nasdaq: ACRX
Biotech developing a Phase 3 treatment for acute post-operative pain.
Industry: Health Care
First Day Return: -9.0%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 11/12/2010 |
| Offer Price | $5.00 |
| Price Range $5.00 - $5.00 | |
| Offer Shares (mm) | 8.0 |
| Deal Size ($mm) | $40 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/10/2011 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $40 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Redwood City, CA, United States |
| Founded | 2005 |
| Employees at IPO | 19 |
| Website www.acelrx.com | |
AcelRx (ACRX) Performance
